Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

25. November 2025 08:30 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

THE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Piper Sandler...
11. November 2025 08:30 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

Lexicon Pharmaceuticals will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18.
08. November 2025 14:30 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that new sotagliflozin clinical data was presented at the AHA Annual Scientific...
06. November 2025 07:30 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

Lexicon Pharmaceuticals reported third quarter 2025 financial results and provided an update on key corporate milestones and accomplishments.
04. November 2025 08:30 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New Orleans

THE WOODLANDS, Texas, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from three studies of sotagliflozin will be presented during upcoming...
30. Oktober 2025 08:30 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

THE WOODLANDS, Texas, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its third quarter 2025 financial results on Thursday,...
14. Oktober 2025 08:00 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

– Results support advancement of 10 mg dose into Phase 3 development – – End-of-Phase 2 meeting request accepted by U.S. FDA; partnership discussions progressing – THE WOODLANDS, Texas, Oct. 14,...
08. Oktober 2025 07:59 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

THE WOODLANDS, Texas, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Yesterday, Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) hosted and participated in a roundtable discussion with experts to explore how to...
22. September 2025 16:00 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Data obtained from ongoing third-party funded, investigator-sponsored trials have been submitted in effort to address the December 2024 complete response letter Company seeks alignment on...
17. September 2025 07:00 ET | Quelle: Lexicon Pharmaceuticals, Inc.

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

THE WOODLANDS, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the presentation of clinical data from the company’s Phase 2b PROGRESS study for...

Nächste Seite